<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980083</url>
  </required_header>
  <id_info>
    <org_study_id>MSE</org_study_id>
    <nct_id>NCT00980083</nct_id>
  </id_info>
  <brief_title>GLP-1 - Regulatory Mechanism of Postprandial Glycemia</brief_title>
  <official_title>Endogenous GLP-1 Regulates Postprandial Glycaemia in Human: Relative Contributions of Insulin, Glucagon, and Gastric Emptying</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Synthetic GLP-1 lowers postprandial (pp) glycemia by stimulating insulin, inhibiting
      glucagon, and delaying gastric emptying. However, the effects of the endogenous peptide are
      largely unknown. Using the specific GLP-1 receptor antagonist exendin(9-39)amide (Ex(9-39))
      the investigators recently showed that GLP-1 released during intestinal meal perfusion acts
      as an incretin hormone and as an enterogastrone. As the relative contributions of these
      effects to controll postprandial glycemia are unclear, the investigators used Ex(9-39) to
      investigate the mechanisms of action of GLP-1 after an oral meal in humans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two experiments were performed in random order in 12 healthy subjects. After a 50-min basal
      period subjects ingested a 412 kcal mixed semisolid meal containing 30g oatmeal, labelled
      with 99mTc-Sn-colloid. Gastric emptying was measured by high-resolution scintigraphy until
      210 min after meal ingestion. Saline (SAL) or Ex(9-39) at 900 pmol/kg/min was intravenously
      infused during the two experiments. In addition, in 6 of the 12 subjects gastric motility was
      measured by antroduodenal manometry and gastric barostat. AUC: pp incremental area under the
      curve. Lag period (LP): time to 10% emptying.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postprandial blood glucose levels</measure>
    <time_frame>-50 min until 210 min after meal intake</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>gastric emptying rate</measure>
    <time_frame>0-210min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma levels of glucagon, insulin</measure>
    <time_frame>-50min until 210 min</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Subjects</condition>
  <condition>Gastric Emptying</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Exendin(9-39)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exendin(9-39)amide</intervention_name>
    <arm_group_label>Exendin(9-39)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subject

          -  &gt;=18 years of age

          -  No medication

        Exclusion Criteria:

          -  Acute disease

          -  Metabolic disease

          -  On medication

          -  Pregnancy, breast feeding

          -  Gastrointestinal surgery

          -  Dyspeptische Symptome (Völlegefühl, Blähungen, abdominelle Schmerzereignisse,
             Übelkeit, Erbrechen, Sodbrennen)

          -  Teilnahme an einer klinischen Studie in den vergangenen 6 Monaten
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joerg Schirra, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Munich, Department of Internal Medicine II, Munich, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine II, University of Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2009</study_first_submitted>
  <study_first_submitted_qc>September 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2009</study_first_posted>
  <last_update_submitted>September 17, 2009</last_update_submitted>
  <last_update_submitted_qc>September 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>University of Munich</name_title>
  </responsible_party>
  <keyword>GLP-1</keyword>
  <keyword>exendin(9-39)</keyword>
  <keyword>gastric emptying</keyword>
  <keyword>incretin</keyword>
  <keyword>human</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

